BioSpace News Archive

Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended September 30, 2019 and provided a company update.

scPharmaceuticals Inc. announced that John Tucker, chief executive officer, will present and host investor meetings at the Jefferies 2019 London Healthcare Conference being held at the Waldorf Hilton in London, UK.

Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, announced that company management will be presenting at the following investor conferences

NGM Biopharmaceuticals, Inc. announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference in New York, NY on Tuesday, November 19, 2019 at 3:00 p.m. ET.

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including prostate, colorectal and leukemia, today announced new positive data from its Phase 2 trial evaluating onvansertib in combination with Zytiga®

Cardax, Inc. (OTCQB:CDXI) announced results for the third quarter of 2019.

Hoth Therapeutics, Inc. (Nasdaq: HOTH) (“HOTH” or the “Company”), a biopharmaceutical company focused on developing new generation therapies for dermatological disorders such as atopic dermatitis, chronic wounds, psoriasis and acne, today announced, in partnership with the George Washington University (GW),

Afya Limited, or Afya (Nasdaq: AFYA), today announced that it will report third quarter 2019 financial results for the period ended September 30, 2019, before the opening of the market on Monday, December 2, 2019.

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019, at 5:20 p.m. GMT (12:20 p.m. EST).

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, today announced it ranked number 10 in Deloitte’s 2019 Technology Fast 500™